Introduction
Marrow fibrosis (MF) is known to affect bone marrow in numerous neoplastic diseases resulting from an overproduction of collagen type I and III fibers by usually non-neoplastic bone marrow fibroblasts stimulated by tumor cell-derived cytokines. [1] [2] [3] [4] MF appears to provide independent prognostic information during the course of chronic myeloproliferative disorders. [5] [6] [7] The World Health Organization (WHO) classification of myelodysplastic syndromes (MDS), 8 which has been discussed controversially, 9, 10 considers numerous morphologic, cytogenetic and clinical features known to provide prognostic information not mentioned in the French-American-British classification 11 including histopathologic features, such as an atypical localization of immature precursors (ALIP). 8 However, occurrence of fibrosis is not mentioned in the disorders summarized in the section 'Myelodysplastic Syndromes', 8 and up to now, there have been no data on the frequency of MF within this new classification system. Previous publications reporting on the occurrence of MF in a relevant proportion of patients with an MDS are more than 10 years old, [12] [13] [14] [15] [16] [17] they are based on rather small numbers of patients, 15, 16, 18 or they differ in their results on the frequency and significance of MF. 12, 13, 16, 19 Therefore, we performed a retrospective study on the occurrence and significance of MF, relating the results to the WHO classification of MDS and the International Prognostic Scoring System (IPSS). 20 
Patients and methods

Study design
A total of 200 patients with primary MDS and 33 patients with fibrotic stage of chronic idiopathic myelofibrosis (CIMF) 21 according to the WHO classification treated in more than 20 hematology centers all over Germany were extracted from our bone marrow registry according to the following inclusion criteria: (1) All patients had been admitted to the hematology center within the last two decades because of an unclear cytopenia without any history of a neoplastic disorder or another life-threatening hematologic disease. (2) Their bone marrow had been aspirated and biopsied by colleagues that use bone marrow biopsies (BMBs) as a standard in the diagnosis of any unclear cytopenia, planning up-front for every patient to have aspirate and biopsy for initial diagnosis of the cause of unclear cytopenia, (3) sending all the BMBs from their patients with cytopenia(s) to our hematopathology department, (4) aspirating the bone marrow from all patients with a myeloid neoplasm for cytogenetic evaluation within 4 weeks after diagnosis of the hematologic neoplasm, and (5) sending all the samples for the cytogenetic evaluation to our Institute of Cell and Molecular Pathology. (6) The diagnostic BMBs and aspirates were adequate for the histopathologic and cytogenetic analyses. (7) None of these patients had been pretreated by a cytoreductive therapy regimen prior to the diagnostic BMBs and aspirates. Among the CIMF patients, only those with full-blown MF and whose BMBs were evaluable for the V617F mutation in the JH2 pseudokinase domain of the Janus kinase 2 (JAK2) were extracted.
The patients with CIMF served as a control group for MDS patients with fibrosis to check for similarities and differences in hematopathologic, cytogenetic and molecular genetic findings. The patients with primary MDS according to the WHO classification served as the evaluation group to estimate the risk and prognostic significance of MF in MDS. The study was conducted in accordance with the Declaration of Helsinki and the regulations of the Central Ethical Committee of Hannover Medical School.
Diagnosis and classification
The diagnosis of an MDS or CIMF was made by an experienced hematopathologist using the criteria described by the WHO 8, 21 with exclusion of other causes which may lead to a dysmyelopoiesis or atypical features of hematopoiesis. The slides from bone marrow aspirate and peripheral blood smears were reevaluated decentrally by expert hematologists of the hematology centers whereas the BMBs were centrally re-evaluated by an expert hematopathologist from our department using the WHO criteria of classification. 8, 21 When the results differed, the slides from bone marrow aspirate were re-evaluated by an expert hematopathologist from our hematopathology department or the biopsy and aspirate smear slides were discussed at the microscope to come to an agreement. Cases with dry marrow aspirates in the morphologic evaluation, but sufficient number of metaphases in the cytogenetic analysis were not excluded because of their correlation with an MF.
BMBs. A total of 349 BMBs (MDS patients) and 33 BMBs (CIMF patients) were re-evaluated for morphologic changes of hematopoiesis, MF and ALIP by an expert hematopathologist. BMBs from 145 other patients with primary MDS who were not included in the study population were admixed with the other BMBs and evaluated for MF to check the reproducibility of diagnosis and grading of MF. The BMBs were 68.0 ± 35.0 mm 3 in average size (±s.d.) with 24.8±12.8 mm 2 mean area (±s.d.) of marrow evaluable on the slides reviewed. 297/382 BMBs were embedded in methyl-methacrylate without previous decalcification, and 85 in paraffin (WAX) after ethylene-diamine tetra-acetic acid decalcification. All BMBs were cut to a consistent thickness of 3 mm.
Atypical localization of immature precursors were diagnosed as described earlier. 8, 15, 17, 22 The collagen and reticulin fibers were marked with Gomori silver impregnation, and all BMBs were centrally re-cut and re-stained in our hematopathologic laboratory for re-evaluation using the same staining protocol for all biopsies to guarantee constant conditions. MF was evaluated by blinding the examiners to the patients' data and using a semiquantitative approach. 5, 23 Following the results from a previous systematic analysis of a pathologic fiber increase within bone marrow, 23 a 'normal fiber content' was diagnosed when 495% of marrow area ( ¼ V M ) did not show any fiber increase. 'MF' was diagnosed when X15% of V M showed an increase of reticulin fibers, 23 and 'extensive diffuse MF' was diagnosed when X50% of V M was affected by fibrosis. 'Foci with an increased fiber deposition' (FFI) affecting 5-14% of V M , which did not fulfill the criteria to diagnose a fibrosis, but which may precede MF, 7 were registered separately (examples: see Supplementary Figure 1 ). The birefrigence of fibers in polarized light was used to speed up the detection of FFI and focal MF. To simplify the estimate in cases with an inhomogeneous focal fiber increase in bone marrow, a microscope with a measuring ocular and a 10 Â 10 grid was used, estimating the proportion with a fiber increase by the proportion of the grid which covers the marrow regions with a fiber increase.
The reproducibility of this approach was tested by two other expert hematopathologists each blinded to the results of the other and to patients' data. They re-evaluated 200 BMBs, 100 randomly selected among those previously graded as 'normal fiber content' and 100 among those previously diagnosed as 'FFI' or 'MF'. 55/200 BMBs came from the MDS population presented in this article, 145 from other patients with primary MDS who were not included in the study population.
Cytogenetic evaluation. From all patients, bone marrow aspirates were systematically evaluated for chromosomal aberrations. Consideration of the karyotype required a minimum of 20 metaphases in cases without an MF and a minimum of 10 in cases with an MF, evaluated within 4 weeks after diagnosis of MDS and reviewed by an expert cytogeneticist. Chromosomes of marrow cells were evaluated by standard procedures. Fluorescence R-banding analysis was performed by staining with chromomycin A3 and counterstaining with methyl green as described earlier. 24 Cytogenetic findings were described according to ISCN 1995, 25 and among the patients with an MDS, the cytogenetic risk groups were defined as described by the International Prognostic Scoring Group. 20 JAK-2 V617F mutation. A V617F mutation in the JH2 pseudo-kinase domain of the JAK2 is a typical feature of CIMF, 26 but may also occur in myelodysplastic/myeloproliferative disorders, 27 in patients with del(5q) chromosome abnormality, 28 and in a minority of other patients with MDS, 29 possibly in those with an MF. 30 Therefore, the BMBs with MF were evaluated for cells with JAK2-V617F mutation. DNA was extracted from all marrow cells within a 10 mm slide taken from the biopsy. DNA extraction, JAK2 amplification, BsaX I restriction site analysis, JAK2 (V617F) genotyping and allele quantification by pyrosequencing were performed as described earlier. 26 
Treatment and follow-up evaluation
All patients with MDS were treated with the best supportive careFincluding the administration of erythropoietin or G-CSF. Patients treated with anti-angiogenic, immunomodulatory or hypomethylating drugs were not included in this study. Additional short courses (that is p3 months) of low-dose oral chemotherapy, which were applied to 43 patients were not an exclusion criterion since they did not influence the results. 64 patients received intensive chemotherapy (three of them with a stem cell allograft) or long courses (that is 43 months) of lowdose oral chemotherapy during the further course of disease. When analyzing the risk of MDS-related life-threatening complications, the follow-up of these patients was not censored, assuming that fatal marrow failure or transformation into AML were caused by the MDS rather than the chemotherapy. All the other follow-up analyses (overall survival times, risk of MF and risk of AML) were restricted to the periods with the best supportive care by censoring the follow-up of these 64 patients at the start of chemotherapy. The treatment of the patients with CIMF was not considered since their follow-up was not analyzed.
The MDS patients were monitored by the hematologist, who performed the treatment, in 3-6-month intervals with respect to changes in peripheral blood cell counts, blast counts in bone marrow and the occurrence of life-threatening events related to disease. In all, 76 patients without and nine with initial MF had agreed to serial BMBs in 6-12-month intervals with respect to the evolution of an MF, covering a histopathologic follow-up period of 1 year in median. A transformation into an acute myeloid leukemia (AML) was defined as a blast count in blood or bone marrow X20%. 8 The follow-up of the patients was censored when another malignant tumor was detected. During a median follow-up period of 3 years with best supportive care, 79 patients with MDS died and 41 suffered from AML.
Statistical analyses
The w 2 test and logistic regression analysis were used to test for differences between patient groups and MDS subtypes, and to study the correlation between MF and other variables. The logrank test and the Cox proportional hazard model were used to test for the significance of variables on the occurrence of MF during the course of disease, occurrence of life-threatening events related to marrow insufficiency (bleeding, infections), transformation into AML and death of patients. When evaluating the prognostic significance of MF emerging during the follow-up of disease, it was included as a time-dependent covariate in the statistical model programming as '0' for the period before and as '1' after detection of MF. Probabilities Po0.05 (two-tailed testing) were regarded as 'significant'.
Results
Reproducibility of grading of fibrosis
Among the 200 BMBs re-evaluated by two examiners, the diagnosis 'normal fiber content' versus 'FFI' was confirmed in 80%, 'FFI' versus 'MF' in 88.5% and 'focal MF (p50%)' versus 'diffuse MF (450% of marrow volume)' in 92.5% of cases (k±s.e.: 0.73±0.04; four categories).
Occurrence of MF
A fiber content indistinguishable from normal healthy marrow was observed in the marrow from 73% of MDS patients (details: Table 1 ). Focal MF involving o50% of V M was detected in 5.5% and extensive diffuse fibrosis involving X50% of V M in 6.5% of patients (examples: see Supplementary Figure 1 ). MF occurred significantly more often in patients with evidence of a multilineage dysplasia or a clonal karyotype abnormality (Po0.007), and it was detected more often in patients with a normal marrow cellularity (10/41 ¼ 24.4%) than in those with a hypo-(4/25 ¼ 16%) or a hypercellular (10/134 ¼ 7.5%) bone marrow (P ¼ 0.01). MF furthermore correlated with a more severe thrombopenia, and a higher percentage of blasts in the peripheral blood (Po0.002).
Among the various MDS subtypes, 8 the incidence of MF varied between 0% (RARS) and 16% (RAEB, RCMD; Po0.007; Figure 1a ). MF also occurred significantly more often in patients with a high or int-2 risk (11/53 ¼ 20.8%) than in those with low or int-1 risk (13/147 ¼ 8.8%; P ¼ 0.0281; Figure 1b) . However, the frequencies of MF did not differ significantly between patients with a high or int-2 risk on the one hand and those with low or int-1 risk on the other (P40.1; Figure 1b ).
FFI and evolution of MF during follow-up. In 15% of MDS cases, FFI were detected in the diagnostic bone marrow biopsy. During a median histopathologic follow-up period of 1 year, obvious MF emerged in 42.9%. (3/7) of patients with FFI, a frequency five times higher than in the group with an initial normal fiber content (6/69: 8.7%; P ¼ 0.04). In 2/6 patients without initial FFI, but with MF during the further follow-up, FFI had emerged in a follow-up biopsy prior to the detection of full-blown MF.
Full-blown MF did not reverse during treatment with the best supportive care (n ¼ 5, 1 year median follow-up), but in four other cases after start of (intensive) chemotherapy.
JAK2-V617F mutation in MDS with MF; similarities and differences to CIMF
From the BMBs of a total of 16 MDS patients with MF, a sufficient amount of DNA could be extracted. Two of them showed the JAK2 mutation V617F in 5.8 and 45.1% of alleles. Both disorders showed MDS-typical changes of hematopoiesis with transformation into AML within 6 months after diagnosis of disease. On the other hand, more than 60% of CIMF patients showed the JAK-2-V617F mutation in their bone marrow cells affecting 41.4±20.3% of alleles (mean±s.d.; P ¼ 0.0009 for the difference).
MDS patients with MF in the diagnostic or a follow-up biopsy did not differ from the CIMF patients in the age distribution and the ratio of male to female patients (P40.1). They furthermore differed from the CIMF control group neither in the blast content of the peripheral blood and bone marrow nor in the degree of fibrosis within bone marrow (Table 2 ). However, they differed markedly in the probability and degree of splenomegaly, the probability of a leukocytosis and the degree of cytopenias ( Table 2 ). Most significant differences were observed in the morphologic, cytogenetic and molecular genetic changes of hematopoiesis (Table 2 ). In particular, dysplastic features in at least 10% of cells of granulo-or erythropoiesis or ALIP were not detected in patients with CIMF, but in the majority of the patients with fibrotic MDS. A third of patients with fibrotic MDS showed a pathologic iron storage with occurrence of ringed sideroblasts or a marrow siderosis whereas the majority of CIMF patients showed a sideropenia within bone marrow. Two-thirds of MDS patients showed a clonal karyotype abnormality, often involving chromosomes 5 and 7 (del(5q), monosomy 7), whereas clonal karyotype abnormalities were detected in less than 10% of CIMF patients which involved chromosomes other than 5 and 7.
Both entities showed dysplastic features of megakaryopoiesis in more than 80% of patients. However, the morphologic changes differed markedly between the two entities ( Table 2) ; whereas all patients with CIMF showed more than 10% giant megakaryocytes with a large hypochromatic nucleus and no multinucleated megakaryocytes, more than 80% of MDS patients showed megakaryocytes with more than one small nucleus or abnormal micromegakaryocytes with a hypolobulated round nucleus. Thus, besides the MF and the blast content, none of the MDS patients showed morphologic changes of marrow that resembled CIMF. Changes of trabecular bone, such as an osteosclerosis, were also not detected in the BMBs of the patients with fibrotic MDS, but in 30% of patients with CIMF (Table 2) .
MF and course of MDS
MDS patients with MF in their BMB died significantly earlier than patients with an initial normal fiber content (Pp0.0005; Table 3 , Figures 1c and d) from complications related to disease, such as severe bleeding, infections, or a transformation into an AML (Table 3 , Figures 2a and b) whereas the risk of death not related to MDS was not increased (not illustrated). Among the causes of death, the probability of a fatal bleeding was markedly increased (P ¼ 0.005). In patients still surviving, disease-related life-threatening events also occurred significantly earlier when MF had been detected in the diagnostic BMB (Figure 2c ; Po0.002). The prognostic impact of MF was independent of the degree of fibrosis: the survival time of the patients with extensive MF affecting 450% of marrow volume was not shorter than that of the patients with focal MF (P40.05); evidence of MF affecting 415% of marrow volume was the crucial factor in the statistical analyses (Po0.0005). In patients who suffered from MF during the further course of disease, the life expectancy was reduced to the same extent as observed in the patients with an MF in their diagnostic BMB (Table 4, Figure 2d ; the follow-up of the four patients whose MF reversed during intensive chemotherapy was censored at the start of chemotherapy).
In multivariate analysis, the predictive impact of initial MF on transformation into AML, overall survival time and the probability of fatal marrow failure (MDS-related death) was independent of all the other variables (Table 3) , the classification On the day when the initial BMB was taken (patients with a previous blood transfusion were excluded). c 50% of MDS patients with a leukocytosis and 44% with a thrombocytosis showed a del(5q) or À7 chromosome abnormality. d X1 blast per 100 leukocytes. e and significant increase of erythropoiesis. f Defined as X20% blasts in the bone marrow or in the peripheral blood. Censoring the follow-up of the patients who received low-dose chemotherapy for more than 3 months or intensive chemotherapy.
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G Buesche et al of disease and the risk score (Tables 3 and 4 ). This finding did not change when restricting to patients without excess of blasts; in this patient group, MF was the most important independent predictor of fatal marrow failure (MDS-related death; Table 4 ). LDH elevation lost its prognostic significance when MF was taken into consideration. The same was true for ALIP which provided significant prognostic information in univariate survival analysis, but which lost its prognostic significance when MF was taken into consideration (Table 3) . Hypocellularity, which occurred in 12.5% of patients did not provide independent prognostic information (Table 3 ).
The prognostic impact of the IPSS was independent of the WHO classification (Table 4 ). This was due to patients without MF; in the low and intermediate risk groups, the overall survival curves of the patients with MF or FFI did not match the curves of the non-fibrotic patients (Po0.00005), but were similar to the curves of the int-2 risk patients (Figures 1e and f) .
Discussion
Evaluations of prognosis and classification of MDS have been focussed mainly on changes in hematopoiesis and blood cell . In all subtypes, the overall survival time was markedly reduced when MF had occurred irrespective of the blast content (c-d). The increased risk of death mainly concerned patients with low or int-1 risk according to the IPSS (e), their survival time was reduced down to that of the patients with int-2 risk (e-f) and the risk score (IPSS) provided significant prognostic information in patients without MF (Po0.00005), but not in those with MF (P40.1). (c-f) Overall survival analyses; the follow-up of the patients who received low-dose chemotherapy for more than 3 months or intensive chemotherapy was censored at the start of chemotherapy.
counts which indeed provide significant prognostic information and have led to detailed systems of classification and prognostication. 8, 11, 20 The usefulness of these systems is confirmed by our observations and has also been validated by other independent study groups. 9, 31 In the last decade, a significant influence of other cellular and mesenchymal marrow components not involved in the neoplastic clone, but influencing marrow insufficiency and prognosis of MDS was detected. This has resulted in various anti-inflammatory, immunomodulatory or anti-angiogenic approaches, [32] [33] [34] [35] which, indeed, appear to improve the quality of life and prognosis of patients by inducing a hematologic and even a cytogenetic remission in a significant proportion of patients, [32] [33] [34] [35] indicating that the leading symptoms of MDS, the marrow insufficiency and its life-threatening complications, depend considerably on extra-hematopoietic factors. MF is worth considering in this context since it is a fundamental alteration of marrow architecture, which may lead by itself to cytopenias and thus, may aggravate the symptoms of marrow insufficiency. Indeed, this alteration of the marrow mesenchyme correlates with the degree of thrombopenia and the risk of fatal marrow failure, particularly lethal bleeding, infection or death after transformation into AML. Therefore, MF is worthy of note in the treatment concepts of MDS.
Due to the disregard of MF, its molecular basis in MDS is largely unknown as yet. In other hematologic neoplasms, overproduction of fibers results from an overproduction of cytokines produced by neoplastic or inflammatory cells, such as PDGF-a or -b, TGF-b1 or bFGF. [2] [3] [4] However, these cytokines do not sufficiently explain the increased risk of marrow failure observed in MDS patients with MF, and in long-term bone marrow cultures, proliferation and differentiation of normal hematopoietic precursors are sufficiently supported by bone marrow mesenchymal cells from MDS patients. 36 Therefore, other reasons should be taken into consideration.
It is unlikely that a replacement of hematopoietic marrow tissue by MF as observed in the advanced stage of CIMF plays an important role in myelofibrotic MDS since the life expectancy was also markedly reduced when focal MF affecting less than 50% of marrow volume occurred. An unfavorable alteration of the marrow microenvironment, as observed by in vitro evaluations, 37, 38 appears to be a more plausible explanation. MF may be interpreted as an indicator of a more malignant subtype of disease since it correlates with features, which indicate a higher degree of malignancy, such as multilineage dysplasia. MF also correlates with an excess of blasts and, similar to observations in chronic myeloid leukemia, 7 MF may be preceded by abnormal FFI which occur in B15% of patients on the day of diagnosis of disease, observations which furthermore allow MF to be interpreted as a more advanced stage of disease.
Although fibrotic MDS shares some features with CIMF, such as the MF and the increased probability of splenomegaly and immature precursors within the peripheral blood, it cannot be Table 2 MDS with MF on the day of diagnosis or during further follow-up: hematopathologic, cytogenetic and molecular genetic findings on the day when MF was detected; comparison to fibrotic stage of CIMF Occurrence of ringed sideroblasts, iron overload. e 2/16 patients; in the biopsies from the other MDS patients, a sufficient amount of DNA could not be extracted (denaturation of DNA; the CIMF control group comprised only such patients whose BMBs showed a sufficient amount of DNA for the JAK2-V617F mutation analysis).
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confused with this type of chronic myeloproliferation since the morphologic, cytogenetic and molecular genetic changes of hematopoiesis differ completely. In fibrotic MDS, trilineage dysplasia, clonal karyotype abnormalities, particularly of chromosomes 5 (del(5q)) and 7 (monosomy 7) and a low probability of a JAK2-V617F mutation are characteristic, whereas CIMF is characterized by unilineage dysplasia of megakaryopoiesis, normal karyotype, a high probability of a JAK2-V617F mutation and an increased risk of osteosclerosis. Furthermore, the dysplastic features of megakaryopoiesis differ markedly between the two entities. Thus, fibrotic MDS is not a chronic myeloproliferation, but a more malignant variant of the MDSs with an increased risk of MDS-related lethal complications.
Even when including patients with FFI, the high frequencies of MF exceeding 50% of patients with primary MDS as reported by some authors 17, 19 could not be supported by our observations. Considering the strong dependence of the diagnosis of MF on the technical preparation of BMBs 39 and on the approach used to prove MF, 23 the diversity in the reported frequencies appears to reflect technical problems or problems of selection rather than a biological difference. Founding the evaluations on patients whose bone marrow had been planned up-front to be both aspirated and biopsied for initial diagnosis of an unclear cytopenia, it is unlikely that full-blown MF affects more than 30% of patients with primary MDS, an observation which is in agreement with earlier results from other authors. 12, 13 In a minority of patients, MF may be not detectable on the day of diagnosis, but may emerge during the further course of disease. The majority of these patients show FFI in a previous bone marrow biopsy, indicating that fibrosis emerges focally within bone marrow rather than diffusely, an observation similar to the data recently reported from patients with chronic myeloid leukemia. 7 Nevertheless, FFI provided significant prognostic information only when a transformation into full-blown MF affecting 415% of marrow volume occurred. This observation supports the usefulness of the 15% cutoff level for the definition of a pathologic fiber increase, that is MF, as has been published earlier. 23 A pathologic fiber increase was not a specific feature restricted to a few subtypes, and the classification and the differences between the various MDS subtypes could not explain or compensate for the significantly shortened survival Table 3 Prognostic significance of initial marrow fibrosis in the context of other variables (patients with MDS; n ¼ 200) Marrow fibrosis in MDS G Buesche et al Figure 2 Life-threatening bleeding, infection, or AML occurred significantly earlier in patients with MF (a: Risk of AML, c: Risk of MDS-related life-threatening complications among patients still alive) and explained their shorter survival time (b: Risk of MDS-related death) whereas the probability of death due to cardiovascular events, accidents, suicide or disorders not explained by marrow insufficiency or transformation into AML was not increased (not illustrated). In patients who suffered from MF during the further follow-up, the life expectancy was reduced to the same extent as observed in the patients with MF in their diagnostic biopsy (d: Overall survival times after detection of MF). (a, d) The follow-up of the patients who received low-dose chemotherapy for more than 3 months or intensive chemotherapy was censored at the start of chemotherapy. time of patients with MF. This was also true with respect to the IPSS and its variables, the LDH value 40 as well as the evidence of another relevant histopathologic variable, the ALIP. 22 In multivariate survival analysis, MF appears to provide significant independent prognostic information. On the basis of these observations, it is recommended to consider MF as a significant unfavorable prognostic factor in diagnosing and prognosticating disease, and to reassess its prognostic significance in newer anti-inflammatory, immunomodulatory or antiangiogenic therapy concepts. [32] [33] [34] [35] 
